Simcere Acquires Manufacturing Rights For Generic Crestor In China; Hopes Sales Force Will Provide Edge Over Competition
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Chinese firm Simcere signed an agreement with Tianjin Tianda Pharmaceutical to acquire the manufacturing license in China for Tianda's rosuvastatin, a generic version of AstraZeneca's cholesterol and atherosclerosis treatment Crestor (rosuvastatin), Simcere announced Nov. 9
You may also be interested in...
Merck, Simcere Form JV To Expand Access To Lifestyle Drugs Across China
SHANGHAI - Merck & Co. affiliate MSD signed an agreement to form a joint venture July 21 with Simcere Pharmaceutical Group that will see both companies expand access to critical lifestyle drugs across China
Merck, Simcere Form JV To Expand Access To Lifestyle Drugs Across China
SHANGHAI - Merck & Co. affiliate MSD signed an agreement to form a joint venture July 21 with Simcere Pharmaceutical Group that will see both companies expand access to critical lifestyle drugs across China
Merck, Simcere Form JV To Expand Access To Lifestyle Drugs Across China
The deal also signals Merck's partnering strategy in emerging markets for its branded and innovative products, especially in Asia. The company expects EMs to contribute 25% of Merck's global sales by 2013.